We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

18 hedge funds and large institutions have $29.3M invested in GT Biopharma in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

13% more funds holding

Funds holding: 16 → 18 (+2)

0.05% less ownership

Funds ownership: 55.87% → 55.82% (-0.05%)

17% less capital invested

Capital invested by funds: $35.3M → $29.3M (-$6M)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$8.84K
2
Osaic Holdings
Osaic Holdings
Arizona
+$7.12K
3
NFSG
Newbridge Financial Services Group
Florida
+$4.73K
4
TRCT
Tower Research Capital (TRC)
New York
+$3.44K
5
UBS Group
UBS Group
Switzerland
+$2.96K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$23.1K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$2.49K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$384
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$29M – – –
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$88.3K -$2.49K -921 -3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$45.5K -$384 -142 -0.9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$32K – – –
Wells Fargo
5
Wells Fargo
California
$30.5K – – –
BlackRock
6
BlackRock
New York
$29.7K – – –
UBS Group
7
UBS Group
Switzerland
$15.2K +$2.96K +1,093 +28%
Morgan Stanley
8
Morgan Stanley
New York
$10.8K +$8.84K +3,267 +1,228%
TRCT
9
Tower Research Capital (TRC)
New York
$8.9K +$3.44K +1,274 +78%
Osaic Holdings
10
Osaic Holdings
Arizona
$8.07K +$7.12K +2,633 +21,942%
NFSG
11
Newbridge Financial Services Group
Florida
$5.34K +$4.73K +1,750 New
Bank of America
12
Bank of America
North Carolina
$82 – – –
SS
13
SBI Securities
Japan
$49 +$43 +16 New
BBPWM
14
Blue Bell Private Wealth Management
Pennsylvania
$31 – – –
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$18 – – –
FFA
16
Farther Finance Advisors
California
$18 +$16 +6 New
AF
17
Allworth Financial
California
$5 +$5 +2 New
JP Morgan Chase
18
JP Morgan Chase
New York
$3 – – –
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$23.1K -10,105 Closed

GTBP Hedge Fund Activity: Q4 2024 in Review

18 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2024, worth a combined $29.3M — down 17% from $35.3M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new GTBP positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $8.84K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $23.1K sold.

  • 18 institutional investors held GT Biopharma (GTBP) as of Q4 2024, up from 16 in Q3 2024.
  • Funds reported $29.3M of GT Biopharma stock for Q4 2024, down 17% quarter-over-quarter.
  • 4 funds opened new GT Biopharma positions in Q4 2024 and 2 closed out, a net change of +2 holders.
  • The largest GT Biopharma buyer in Q4 2024 was Morgan Stanley, an estimated $8.84K added.
  • The largest GT Biopharma seller in Q4 2024 was Susquehanna International Group, an estimated $23.1K sold.

Based on aggregated 13F filings for Q4 2024.